Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis

Journal of Immunology

Volumn 166, Issue 10, 2001, Pages 6430-6436

  Wang, Hua Bing ^a   Shi, Fu Dong ^b,c   Li, Hulun ^a   Chambers, Benedict J ^c   Link, Hans ^a   Ljunggren, Hans Gustaf ^a,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LYMPHOCYTE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL PROLIFERATION; CONTROLLED STUDY; IMMUNE RESPONSE; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0035873656     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.10.6430     Document Type: Article

References (54)

1. Harper, K., C. Balzano, E. Rouvier, M. G. Mattel, M. F. Luciani, and P. Golstein. 1991. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J. Immunol. 147:1037.
2. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405.
3. Waterhouse, P., L. E. Marengere, H. W. Mittrucker, and T. W. Mak. 1996. CTLA-4, a negative regulator of T-lymphocyte activation. Immunol. Rev. 153: 183.
4. Saito, T. 1998. Negative regulation of T cell activation. Curr. Opin. Immunol. 10:313.
5. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Gnesser, and T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985.
6. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, and A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541.
7. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734.
8. Kathy, M., M. Camberis, and G. L. Gros. 1997. Protective immunity to nematode infection is induced by CTLA-4 blockade. J. Exp. Med. 186:183.
9. Karandikar, N. J., C. L. Vanderlugt, T. L. Walunas, S. D. Miller, and J. A. Bluestone. 1996. CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 184:783.
10. Perrin, P. J., J. H. Maldonado, T. A. Davis, C. H. June, and M. K. Racke. 1996. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 157:1333.
11. Luhder, F., P. Hoglund, J. P. Allison, C. Benoist, and D. Mathis. 1998. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) regulate the unfolding of autoimmune diabetes. J. Exp. Med. 187:427.
12. Drachman, D. 1994. Myasthenia gravis. N. Engl. J. Med. 330:1797.
13. Lewis, R. A., J. F. Sela, and R. P. Lisak. 1995. Myasthenia gravis: immunological mechanisms and immunotherapy. Ann. Neurol. 37:S51.
14. Yokoi, T., B. Mulac-Jericevic, J. Kurisaki, and M. Z. Atassi. 1987. T lymphocyte recognition of acetylcholine receptor: localization of the full T cell recognition profile on the extracellular part of the a chain of Torpedo californica acetylcholine receptor. Eur. J. Immunol. 17:1697.
15. Oshima, M., A. R. Pachner, and M. Z. Atassi. 1994. Profile of the regions of acetylcholine receptor a chain recognized by T-lymphocytes and by antibodies in EAMG-susceptible and non-susceptible mouse strains after different periods of immunization with the receptor. Mol. Immunol 31:833.
16. Hawke, S., H. Matsuo, M. Nicolle, G. Malcherek, A. Melms, and N. Willcox. 1996. Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting. Immunol. Today 17:307.
17. Conti-Fine, B. M., D. Navaneetham, P. I. Karachunski, R. Raju, B. Diethelm-kita, D. Okita, J. Howard, Jr., and Z. Y. Wang. 1998. T cell recognition of the acetylcholine receptor in myasthenia gravis. Ann. NY Acad. Sci. 841:283.
18. Shi, F. D., B. He, H. Li, D. Matusevicius, H. Link, and H. G. Ljunggren. 1998. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis. Eur. J. Immunol 28:3587.
19. McIntosh, K. R., P. S. Linsley, P. A. Bacha, and D. B. Drachman. 1998. Immunotherapy of experimental autoimmune myasthenia gravis: selective effects of CTLA41g and synergistic combination with an IL2-diphtheria toxin fusion protein. J. Neuroimmunol. 87:136.
20. Lindstrom, J., B. Einarson, and S. Tzartos. 1981. Production and assay of antibodies to acetylcholine receptors. Methods Enzymol. 74:432.
21. Deibler, G. E., R. E. Martenson, and M. V. Kies. 1972. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep. Biochem. 2:139.
22. Prabhakar, B. S., G. P. Allaway, J. Srinivasappa, and A. L. Notkins. 1990. Cell surface expression of the 70-KD component of Ku, a DNA-binding nuclear autoantigen. J. Clin. Invest. 86:1301.
23. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol. 155:1032.
24. Berman, P. W., and J. Patrick. 1980. Experimental myasthenia gravis: a murine system. J. Exp. Med. 151:204.
25. Shi, F. D., X. Bai, H. Li, Y. Huang, P. H. van der Meide, and H. Link. 1998. Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals. Clin. Exp. Immunol. 111:506.
26. Li, H., F. D. Shi, B. He, M. Bakheit, B. Wahren, A. Berglof, K. Sandstedt, and H. Link. 1998. Experimental autoimmune myasthenia gravis induction in B cell-deficient mice. Int. Immunol 10:1359.
27. Christadoss, P., J. Lindstrom, S. Munro, and N. J. Talal. 1985. Muscle acetylcholine receptor loss in murine experimental autoimmune myasthenia gravis: correlated with cellular, humoral and clinical responses. J. Neuroimmunol. 8:29.
28. Walunas, T. L., and J. A. Bluestone. 1998. CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J. Immunol 160:3855.
29. Lehmann, P. V., E. E. Sercarz, T. Forsthuber, C. M. Dayan, and G. Gammon 1993. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol. Today 14:203.
30. Lehmann, P. V., T. Forsthuber, A. Miller, and E. E. Sercarz. 1992. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358:155.
31. Lennon, V. A., D. J. McCormick, E. H. Lambert, G. E. Griesmann, and M. Z. Atassi. 1985. Region of peptide 125-147 of acetylcholine receptor α subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies. Proc. Natl. Acad. Sci. USA 82:8805.
32. Rosenberg, J. S., M. Oshima, and M. Z. Atassi. 1996. B-cell activation in vitro by helper T cells specific to region α146-162 of Torpedu californica nicotinic acetylcholine receptor. J. Immunol. 157:3192.
33. Shenoy, M., M. Oshima, M. Zouhair, and P. Christadoss. 1993. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region α 146-162 of acetylcholine receptor. Clin. Immunol. Immunopathol. 66:230.
34. McRae, B. L., C. L. Vanderlugt, M. C. Dal Canto, and S. D. Miller. 1995. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182:75.
35. Vincent, A., L. Jacobson, and P. Shillito. 1994. Response to human acetylcholine receptor α138-199:determinant spreading initiates autoimmunity to self-antigen in rabbits. Immunol. Lett. 39:269.
36. Lennon, V. A., E. H. Lambert, K. R. Leiby, T. B. Okarma, and S. Talib. 1991. Recombinant human acetylcholine receptor α-subunit induces chronic experimental autoimmune myasthenia gravis. J. Immunol. 146:2245.
37. Vincent, A., N. Willcox, M. Hill, J. Curnow, C. MacLennan, and D. Beeson. 1998. Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Immunol. Rev. 164:157.
38. Wu, B., C. Deng, E. Goluszko, and P. Christadoss. 1997. Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis. J. Immunol. 159:3016.
39. Karachunski, P. I., N. S. Ostlie, D. K. Okita, and B. M. Conti-Fine. 1997. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J. Clin. Invest. 100:3027.
40. Baggi, F., F. Andreetta, E. Caspani, M. Milani, R. Longhi, R. Mantegazza, F. Cornelio, and C. Antozzi. 1999. Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. J. Clin. Invest. 104:1287.
41. Karandikar, N. J., T. N. Eagar, C. L. Vanderlugt, J. A. Bluestone, and S. D. Miller. 2000. CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 109:173.
42. Counti-Tronconi, B. M., F. Tang, B. M. Diethelm, S. R. Spencer, S. Reinhardt-Maelicke, and A. Maelicke. 1991. Mapping of a cholinergic binding site by means of synthetic peptides, monoclonal antibodies, and α-bungarotoxin. Biochemistry 29:6221.
43. Link, J., M. Soderstrom, A. Ljungdahl, B. Hojeberg, T. Olsson, Z. Xu, S. Fredrikson, Z. Y. Wang, and H. Link. 1994. Organ-specific autoantigens induce interferon-gamma and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology 44:728.
44. Balasa, B., C. Deng, J. Lee, L. M. Bradley, D. K. Dalton, P. Christadoss, and N. Sarvetnick. 1997. Interferon γ (IFN-γ) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Esp. Med. 186:385.
45. Zhang, G. X., B. G. Xiao, X. F. Bai, P. H. van der Meide, A. Orn, and H. Link. 1999. Mice with IFN-γ receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J. Immunol. 162:3775.
46. Wang, H. B., F. D. Shi, H. Li., P. H. van der Meide, H. G. Ljunggren and H. Link. 2000. Role for IFN-γ in rat strains with different susceptibility to experimental autoimmune myasthenia gravis. Clin. Immunol. 95:156.
47. Mason, D., and F. Powrie. 1998. Control of immune pathology by regulatory T cells. Curr. Opin. Immunol. 10:649.
48. Shi, F. D., H. Li., H. B. Wang, X. Bai, P. H. van der Meide, H. Link, and H. G. Ljunggren. 1999. Mechanism of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells. J. Immunol. 162:5757.
49. Shi, F. D., H. B. Wang, H. Li, S. Hong, M. Taniguchi, H. Link, L. Van Kaer, and H. G. Ljunggren. 2000. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat. Immunol. 1:245.
50. + T cells. J. Exp. Med. 188:1894.
51. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192:303.
52. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192:295.
53. Singh, R. R., and B. H. Hahn. 1998. Reciprocal T-B determinant spreading develops spontaneously in murine lupus: implications for pathogenesis. Immunol. Rev. 164:201.
54. + immunoregulalory T cells that control autoimmune diabetes. Immunity 12:431.